Diazoto Oksidas Gaschema (Nitrous Oxide)

Diazoto Oksidas Gaschema is indicated for several clinical situations where rapid, controllable analgesia or sedation is required.

• Analgesia during routine dental procedures such as extractions, restorations, and prophylaxis.
• Short‑term procedural sedation for minor surgical or diagnostic interventions outside the operating theatre.
• Adjunctive use to reduce the concentration of volatile anesthetics during general anesthesia.
• Management of breakthrough pain in patients already receiving a primary analgesic regimen.
• Use in obstetric settings for labor analgesia where rapid onset and easy titration are desired (off‑label in some jurisdictions).

Inhalation of nitrous oxide can produce a range of physiological responses, most of which are dose‑dependent and transient.

Common

• Light‑headedness or euphoria
• Nausea or mild vomiting
• Tingling sensation around the mouth or extremities
• Increased heart rate (tachycardia) without significant blood pressure change

Serious

• Persistent vomiting leading to aspiration risk
• Hypoxia if administered without adequate oxygen supplementation
• Severe hypertension or arrhythmia in susceptible individuals
• Loss of consciousness or profound sedation beyond intended level

When prescribing or administering Diazoto Oksidas Gaschema, clinicians should observe several safety considerations to minimize adverse outcomes.

• Verify patient’s ability to maintain airway and adequate ventilation before initiation.
• Ensure delivery of supplemental oxygen to prevent hypoxic events.
• Assess for contraindications such as recent middle‑ear surgery, pneumothorax, or severe chronic obstructive pulmonary disease.
• Use the lowest effective concentration and limit exposure duration to the shortest necessary period.
• Monitor vital signs, especially heart rate, blood pressure, and oxygen saturation, throughout the procedure.
• Avoid use in patients with known vitamin B12 deficiency without appropriate supplementation.
• Document the concentration and total exposure time in the patient’s record.

Nitrous oxide may interact with other agents or clinical conditions, influencing its safety profile.

Avoid

• Concurrent use of other central nervous system depressants (e.g., benzodiazepines, opioids) at high doses without close monitoring.
• Administration in patients receiving high concentrations of volatile anesthetics that could potentiate cardiovascular depression.
• Use with agents that increase the risk of nausea and vomiting, such as certain chemotherapeutic drugs, without anti‑emetic prophylaxis.

Use with caution

• Patients taking medications that affect vitamin B12 metabolism (e.g., metformin, proton‑pump inhibitors).
• Individuals with respiratory disorders who are receiving supplemental oxygen therapy.
• Situations where nitrous oxide may expand closed gas spaces, such as recent eye or ear surgery.